weight loss drug news today glp-1 september 2025 Some people taking medications report side effects such as nausea, constipation, stomach upset, or even hair loss. Now, researchers are exploring a new class of weight-loss drugs designed to target obesity From Resolutions to Results—How GLP-1s

The initial dosing regimen of liraglutide is 0.6 mg subcutaneously daily, with the dose increased to up to 3 mg for Saxenda and 1.8 mg for Victoza , usually after one week at the previous dose.40,41 Dulaglutide Dulaglutide is a recombinant fusion protein consisting of two identical 31-aa chains, each covalently linked to a single Fc fragment derived from a modified human IgG4 heavy chain (MW: 59,669.8 g/mol) (Figure 1E).42,43 Dulaglutide (Trulicity , Eli Lilly and Company, Indianapolis, IN, USA) was as a treatment for type 2 diabetes in 2014

Venlafaxine (Effexor) Raises serotonin and norepinephrine

Major Findings: Demonstrated an acceptable safety and tolerability profile

Detection of phytochelatins in the hyperaccumulator Sedum alfredii exposed to cadmium and lead